Tern Plc to exercise warrants in Wyld Networks

Tern - Wyld Networks

Tern Plc (LON:TERN), the company focused on value creation from Internet of Things (“IoT”) technology businesses, has announced that it has committed to exercise the 320,454 TO2 Warrants in Wyld Networks AB which represents all of the TO2 Warrants that were issued to Tern pursuant to its investment as part of Wyld Networks’ Offering in conjunction with Wyld Networks’ IPO and admission to trading on the NASDAQ First North Growth Market in Stockholm on 2 July 2021.

Tern will pay SEK 2,794,359 (approximately £220,000) to exercise its TO2 Warrants to subscribe for 320,454 shares in Wyld Networks at SEK 8.72 per share, and this will be funded from Tern’s existing cash resources.

Prior to the completion of the TO2 Warrant exercises Tern held 46.5% of Wyld Networks’ issued share capital. The subscription period for the in aggregate, 2,275,000 TO2 Warrants commenced on 6 December 2022 and will end on 19 December 2022. If all of the TO2 Warrants are exercised Tern’s holding in Wyld Networks will reduce to 41.0% and a further announcement regarding Tern’s resultant holding in Wyld Networks will be made when the exercise period for the TO2 Warrants is completed.

Capitalised terms not otherwise defined herein have the same meaning as in the Company’s announcement “Proposed IPO of Wyld Networks” made on 9 June 2021.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Tern cuts H1 loss by 60% as portfolio growth and funding strengthen

Tern reduced its first-half loss by 60%, with net asset value improving and further fundraising strengthening the balance sheet. Additional funding has supported Talking Medicines and Device Authority, while continued progress across the portfolio provides further scope for value creation.

AI control of machines creates a new market for device trust

AI is beginning to control physical machines, increasing demand for technology that can verify device identity before those machines are allowed to act.

Peptide drug development expands beyond GLP-1

GLP-1 success is widening interest in peptide drug development, with the next phase focused on proving clinical value across new therapeutic areas.

Tern Plc announces 90% take-up of Open Offer

Tern Plc has received valid acceptances for 50.9 million Open Offer Shares, representing approximately 90% of the shares available. The fully underwritten offer will raise approximately £509,368 before expenses, with admission of the new shares expected on 24 September 2026.

Talking Medicines moves to capture pharma demand for better patient intelligence

Tighter US pharma advertising rules could increase demand for patient intelligence, supporting the relevance of Talking Medicines’ DrugVoice platform.

Tern portfolio company Talking Medicines launches ‘Intent to Prescribe’ DrugVoice application

Talking Medicines has launched a new DrugVoice application combining its Message Resonance Score™ with near-real-time point-of-care data to help pharmaceutical companies assess links between HCP message alignment and prescribing intent.

Search